The estimated Net Worth of Jack A Roth is at least $643 Thousand dollars as of 29 March 2018. Dr Roth owns over 40,000 units of Genprex Inc stock worth over $642,720 and over the last 7 years he sold GNPX stock worth over $0.
Dr has made over 1 trades of the Genprex Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 40,000 units of GNPX stock worth $200,000 on 29 March 2018.
The largest trade he's ever made was buying 40,000 units of Genprex Inc stock on 29 March 2018 worth over $200,000. On average, Dr trades about 40,000 units every 0 days since 2018. As of 29 March 2018 he still owns at least 1,338,999 units of Genprex Inc stock.
You can see the complete history of Dr Roth stock trades at the bottom of the page.
Dr. Jack A. Roth F.A.C.S., FACS, M.D. is the Chairman of Scientific & Medical Advisory Board at Genprex Inc.
Jack's mailing address filed with the SEC is 6516 Brompton Rd, Houston, TX 77005, USA.
Over the last 7 years, insiders at Genprex Inc have traded over $0 worth of Genprex Inc stock and bought 156,300 units worth $607,092 . The most active insiders traders include Ryan M. Confer, Christy M. Nance, and Jack A Roth. On average, Genprex Inc executives and independent directors trade stock every 205 days with the average trade being worth of $14,575. The most recent stock trade was executed by John Rodney Varner on 21 April 2023, trading 19,000 units of GNPX stock currently worth $20,140.
genprex is mapping the future of cancer care. genprex's mission is to address the unmet medical needs of a growing population of cancer patients worldwide, through the development of a novel class of cancer drugs: immunogene therapy. our revolutionary clinical-stage products work synergistically with other approved and pipeline drugs to expand clinical indications for various cancers. about oncoprex® and lung cancer lung cancer is the second most common cancer in the u.s. but the leading cause of cancer death. there are approximately 225,000 new lung cancer cases in the u.s. per year and 1.8 million worldwide. the 5-year survival rate of stage iv non-small cell lung cancer (nsclc) is less than 1%, and treatment options beyond chemotherapy are lacking. approved nsclc targeted treatment options outside of chemo/radiation therapies only benefit a minority of patients. oncoprex® may now fill that gap by offering a targeted treatment option for a majority of nsclc patients. oncoprex® is cur
Genprex Inc executives and other stock owners filed with the SEC include: